Catalyst Pharmaceuticals
Diana Gabe, CPA, has a diverse work experience spanning various roles and companies. Diana began their career as a Payroll Administrator at Star Casualty Insurance Company in 2011. Diana then joined PwC in 2012 as an Intern and later became an Assurance Associate. In 2013, Diana worked at Scott Henry & Associates as an Administrative Assistant, where they were responsible for bank statement reconciliation and payroll calculations. Diana returned to PwC in 2015 as a Senior Associate and was promoted to Manager in 2018. Diana'stenure at PwC ended in 2019 when they joined Catalyst Pharmaceuticals, Inc. as a Controller. In 2021, Diana was promoted to the role of Senior Director of Finance & Accounting at Catalyst Pharmaceuticals, Inc.
Diana Gabe, CPA, obtained a Bachelor of Business Administration degree in Accounting from Florida Atlantic University in 2011. Prior to that, they studied Hospitality Management at the University of Central Florida from 2007 to 2009. In May 2019, Diana obtained a certification in Digital Acumen from PwC.
Catalyst Pharmaceuticals
2 followers
Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.